Welcome to our dedicated page for Mesa Laboratories SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mesa Laboratories SEC filings document the company's life sciences tools and critical quality control business, its Nasdaq-listed common stock and formal disclosures around operating results, governance and capital structure. Form 8-K reports furnish quarterly financial releases, record annual meeting voting outcomes and report executive succession, director changes and related compensation arrangements.
Other filings and exhibits describe the company's credit facility borrowings, convertible note settlement funding, independent auditor ratification, board committee structure and proxy compensation disclosures. These records frame Mesa's disclosure obligations across its four operating divisions and its financing, shareholder-vote and leadership-transition matters.
Mesa Laboratories CAO Lyndsey Elizabeth Crennen reported a mix of equity compensation events and a small tax-related share sale. On June 18, 2026, she exercised restricted stock units and performance share units for a total of 726 shares of common stock and received a 263-share grant, all as direct holdings. A subsequent sale of 442 shares of common stock on June 22, 2026 at $89.502 per share was executed to cover taxes related to the June 18, 2026 vesting of RSUs and PSUs and occurred under a 10b-1 plan, according to the footnotes. Following these transactions, she directly holds 2,020 shares of Mesa Laboratories common stock.
Mesa Laboratories senior vice president of operations Brian David Archbold reported a mix of stock compensation activity and a modest sale of common shares. On June 18, 2026, he received a grant or award of 1,859 shares of common stock and exercised restricted stock units (RSUs) covering a total of 3,324 shares, converting them into common stock at a stated price of $95.10 per share for reporting purposes. Related RSU entries show derivative positions being fully converted into common stock.
On June 22, 2026, Archbold executed an open-market sale of 2,516 shares of Mesa Laboratories common stock at an average price of about $89.50 per share. After these transactions, he directly holds 6,377 common shares, indicating that a portion of the newly acquired stock was retained while some was sold for liquidity.
Mesa Laboratories CFO John Sakys reported multiple equity transactions in Mesa Laboratories common stock. On June 18, 2026, he received a grant of 2,282 shares of common stock and exercised restricted stock units (RSUs) that converted into 2,756 and 1,036 shares of common stock.
On June 22, 2026, he sold 2,827 shares at an average price of $89.502 per share. A footnote states these shares were sold to cover taxes related to the vesting of RSUs and performance share units on June 18, 2026, and that the transaction was executed under a Rule 10b5-1 trading plan.
After these transactions, Sakys held 19,785 Mesa Laboratories shares directly, plus 50 shares indirectly as custodian for his children.
MLAB submitted a Rule 144 notice reporting proposed resale of 2,827 shares of Common Stock tied to restricted stock vesting. The filing lists a broker-dealer Fidelity Brokerage Services LLC and an aggregate dollar figure of $253,021.88 on the cover. The excerpt also shows 1,223 shares sold on 06/16/2026 for $123,849.54 as transactions in the prior three months.
MLAB files a Form 144 notice to sell 2,516 shares of Common Stock. The filing lists 2,516 shares associated with a Restricted Stock Vesting event dated 06/18/2026. It also reports 1,151 shares sold during the prior three months on 06/16/2026 with an associated figure of $116,558.32.
Mesa Laboratories senior vice president of operations Brian David Archbold reported an open-market sale of company stock. On June 16, 2026, he sold 1,151 shares of Mesa Laboratories common stock at an average price of $101.267 per share. After this transaction, he continues to hold 3,710 shares directly.
Mesa Laboratories Chief Accounting Officer Lyndsey Elizabeth Crennen reported an open-market sale of common stock. On June 16, 2026, she sold 118 shares of Mesa Laboratories common stock at an average price of $101.267 per share. According to the footnote, the shares were sold to cover taxes due on restricted stock units (RSUs) that vested on June 15, 2026, indicating a tax-related transaction rather than a discretionary portfolio move. Following this sale, Crennen directly holds 1,473 shares of Mesa Laboratories common stock.
Mesa Laboratories CFO John Sakys reported an insider transaction involving company common stock. On June 16, 2026, he sold 1,223 shares in an open-market sale at $101.267 per share to cover taxes arising from the vesting of restricted stock units on June 15, 2026. After this sale, he directly holds 16,538 Mesa Laboratories shares. In addition, 50 shares are held indirectly for his children, where he acts as custodian.
Mesa Laboratories Inc. executive Lyndsey Elizabeth Crennen, Chief Accounting Officer, has filed an initial statement of ownership showing her equity stake in the company. The filing lists existing holdings and does not report new open‑market trades.
She directly holds 1,863 shares of Common Stock. In addition, she holds several non‑qualified stock option awards, including options over 369 shares at an exercise price of $268.85 per share expiring on September 1, 2027, 488 shares at $185.57 expiring on June 15, 2028, and 646 shares at $131.67 expiring on June 21, 2029.
Crennen also holds multiple restricted stock unit (RSU) awards, each representing a contingent right to receive one share of common stock. These RSUs cover blocks such as 1,800 shares, 1,443 shares, 735 shares, 542 shares, 465 shares, and 125 shares, with vesting schedules that extend in tranches through 2029.